IPO - Check IPO Date, Price, Lot Size

Anthem Biosciences Ltd IPO

The Company is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. The Company provides end to end CRDMO services and it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Our CRDMO platform comprises 5 main modalities (RNAi, ADC, peptides, lipids and oligonucleotides) and 4 manufacturing capabilities (custom synthesis, flow chemistry, fermentation and biotransformation). The Company derives revenue primarily from its CRDMO services, including developmental and commercial manufacturing, and research and development services. It also generate revenue from the manufacture and sale of specialty ingredients.

Anthem Biosciences Ltd IPO Details

Total Shares Offered

₹ 5,95,61,404

Offer to Public

5,95,61,404

Retail Max (Shares)

₹ 2,07,95,833

Pre Issue Promoters Holding

₹ 43,17,47,949

Exchange

BSE

Issue size

₹ 3395 Cr

IPO Open Date

Jul 14, 2025

Close Date

Jul 16, 2025

Lot Size

Min Investment

₹ 14,040

Issue Type

Book Building

Listing Date

Jul 21, 2025

Anthem Biosciences Ltd IPO Dates

Jul 14, 2025

Opening date

Jul 16, 2025

Closing date

Jul 17, 2025

Basis of Allotment

Jul 18, 2025

Initiation of Refunds

Jul 18, 2025

Credit of Shares

Jul 21, 2025

Listing date

Details

Sector	Type
Sector	Pharmaceuticals - Indian - Bulk Drugs & Formln
Sub Sector	NA
Issue Type	Book Building

Subscription Status

*Values are in Lakhs

Investor Type	Subscription Times	Shares Offered*	Shares Bid*
QIB	77.12x	29708334	2291095976
NII	44.71x	8912500	398469578
Retail	5.96x	20795833	123847828
Employee	7.67x	144737	1110746
Total	47.25x	59561404	2814524128

Investor Type

QIB

NII

Retail

Employee

Total

Subscription Times

77.12x

44.71x

5.96x

7.67x

47.25x

29708334

8912500

20795833

144737

59561404

2291095976

398469578

123847828

1110746

2814524128

Anthem Biosciences Ltd Financial Status

Income Statement

Particulars (In Rs. Crores)

Balance Sheet

Particulars (In Rs. Crores)

Particulars (in Rs. Crores)	FY23	FY22	FY21
Revenue from operations	1,844.55	1,419.37	1,056.92
EBITDA	867.30	647.75	625.18
PAT	506.19	374.78	385.67
Total Assets	1,289.34	1,027.83	851.66
Share Capital	111.82	111.82	114.10
Total Borrowings	300.82	309.43	210.57
Operating Activities (Net Cash)	584.13	456.27	449.37
Investing Activities (Net Cash)	475.27	315.86	355.77
Financing Activities (Net Cash)	300.82	309.43	210.57
Net Cashflow	310.95	183.85	342.79

About Anthem Biosciences Ltd

Anthem Biosciences Limited was originally incorporated as Anthem Biosciences Private Limited under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by the Registrar of Companies, Karnataka at Bengaluru (RoC). Subsequently, the Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of its Shareholders held on October 18, 2024 following which the name of the Company was changed to Anthem Biosciences Limited and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.

According to the F&S Report, the global pharmaceutical industry is projected to grow to U.S.$ 2,076.0 billion by 2029, and CROs and CDMOs are increasingly combining their services to establish integrated CRDMO business models. According to the F&S Report, the Indian CRDMO industry is expected to grow at a CAGR of 13.4% from 2024 to 2029 to reach an estimated value of U.S.$ 15.4 billion, which outpaces the global industry rate of 9.1% and other markets, although pharma companies are subject to challenges such as cost pressures, low rate of experimental compounds moving to commercialization stage and increased regulatory oversight.

Peer Comparison:

Anthem Biosciences Ltd.
Syngene Internatio nal Limited
Sai Life Sciences Limited
Cohance Lifescienc es Limited
Divi's Laboratori es Limited

Anthem Biosciences Ltd Key Points

Strengths

The Company offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.

Its innovation-focused approach has enabled it to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.

Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products,

Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.

Risk

Its business depends on the demand for the company CRDMO services, which contributed to 81.65% of its revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they operate may have a material adverse effect on the company business.

Developmental and commercial manufacturing contributed to 70.78% of its revenue from operations and 71.90% of the company total number of Projects in Fiscal 2025. Its business may be adversely affected by a failures in early phase developmental Projects or a failures to develop or manufacture commercially viable drugs, including for reasons that are not within its control.

Its financial performance is dependent on the success of the molecules the company manufacture, and its revenue from operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failures of a phase III molecule and withdrawal of a commercialized molecule. Accordingly, any unfavorable developments affecting these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of commercialized molecules, may have an adverse impact on its business, financial condition, results of operations and prospects.

Strategy

Continue to expand its technological capabilities to gain wallet share and to win new customers in the discovery and development phase.

Leverage on its manufacturing capacity to cater to the expected increase in commercialized and late stage molecules.

Focus on growing its complex specialty ingredients business with large market opportunity.

Complement its overall growth through identifying opportunities for inorganic expansion.

How To Apply for Anthem Biosciences Ltd IPO Online?

Step 1:

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

FAQs on IPO (Initial Public Offering)

What is the issue size of the Anthem Biosciences Ltd IPO?

Anthem Biosciences Ltd's IPO offers shares for up to 0 It begins on Jul 14, 2025 and ends on Jul 16, 2025.

What is the price of the Anthem Biosciences Ltd IPO?

The price of Anthem Biosciences Ltd IPO ranges between ₹540 to ₹570 per share.

What are the open and close dates for the Anthem Biosciences Ltd IPO?

The Anthem Biosciences Ltd IPO opens on Jul 14, 2025 and closes on Jul 16, 2025.

When will the Anthem Biosciences Ltd IPO be allotted?

The allotment for the Anthem Biosciences Ltd IPO will be finalised on Jul 17, 2025. The shares will be listed on BSE and NSE on Jul 21, 2025.

What is the minimum lot size required for Anthem Biosciences Ltd IPO?

The minimum lot size for Anthem Biosciences Ltd IPO is 26 shares, priced between ₹540 to ₹570 per share.

What is the GMP of Anthem Biosciences Ltd IPO?

The GMP (Grey Market Premium) of Anthem Biosciences Ltd IPO fluctuates based on market demand and sentiment.

How do you check the allotment status of Anthem Biosciences Ltd IPO?

To check the allotment status of Anthem Biosciences Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

Where is the Anthem Biosciences Ltd IPO getting listed?

The Anthem Biosciences Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Jul 14, 2025, and closes on Jul 16, 2025. The allotment is finalised on Jul 17, 2025.

How do you apply for the Anthem Biosciences Ltd IPO?

To apply for the Anthem Biosciences Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.